Cargando…
Review of inflammatory bowel disease and COVID-19
The first cases of a novel corona virus infection were reported in Wuhan China in December of 2019, followed by the declaration of an international pandemic by the World Health Organization in March 2020. Early reports of the virus, now known as severe acute respiratory syndrome coronavirus 2, and i...
Autores principales: | Sultan, Keith, Mone, Anjali, Durbin, Laura, Khuwaja, Samreen, Swaminath, Arun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545397/ https://www.ncbi.nlm.nih.gov/pubmed/33088153 http://dx.doi.org/10.3748/wjg.v26.i37.5534 |
Ejemplares similares
-
Corticosteroid and Biologic Use Not Associated With Adverse Outcomes for Inflammatory Bowel Disease Patients Hospitalized With COVID-19
por: Sultan, Keith, et al.
Publicado: (2021) -
Fatigue in Inflammatory Bowel Diseases: Etiologies and Management
por: Nocerino, Angelica, et al.
Publicado: (2019) -
Ideal Vial Size for Infliximab in the Treatment of Inflammatory Bowel Disease: An Analysis of Pharmaceutical Waste and Physician Opinions
por: Schachne, Jonathan M, et al.
Publicado: (2021) -
Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation
por: Oseni, Ellen A., et al.
Publicado: (2023) -
A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application
por: Becher, Noah, et al.
Publicado: (2022)